Novel antiplatelet drugs in clinical development
The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold prom...
Saved in:
| Published in | Thrombosis and haemostasis Vol. 110; no. 5; p. 868 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Germany
01.11.2013
|
| Subjects | |
| Online Access | Get more information |
Cover
Loading…
| Abstract | The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio. |
|---|---|
| AbstractList | The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio. |
| Author | Ungerer, M Münch, G |
| Author_xml | – sequence: 1 givenname: M surname: Ungerer fullname: Ungerer, M email: ungerer@advancecor.com organization: M. Ungerer, Advancecor GmbH, Fraunhofer Str. 17, 82152 Martinsried, Germany, E-mail: ungerer@advancecor.com – sequence: 2 givenname: G surname: Münch fullname: Münch, G |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24108565$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1jj1PwzAUAD0U0S82ZuQ_YHi2n117RBVQpAqWdq4c-wUFOU6UpEj8e5Cg0y2n0y3ZrHSFGLuVcC-lhYfDTmoBSgA4nLEFaARhFZo5W47jJ4C06M01myuU4Iw1CwZv3RdlHsrU9DlMlGniaTh_jLwpPOamNDFknuhX6vqWyrRmV3XII938c8WOz0-H7U7s319et497EdH5ScTaVtHoWgYH2kerKGwwOfQKfVCElTXRUMRIlXSbhAGdITJWJ6-8TqRW7O6v25-rltKpH5o2DN-ny7r6AVCtROo |
| CitedBy_id | crossref_primary_10_1016_j_fitote_2020_104709 crossref_primary_10_1002_cmdc_201700522 crossref_primary_10_1016_j_prostaglandins_2019_106353 crossref_primary_10_1161_ATVBAHA_114_303413 crossref_primary_10_3390_biomedicines12122855 crossref_primary_10_1007_s11883_015_0501_1 crossref_primary_10_1016_j_pharmthera_2018_08_004 crossref_primary_10_1016_j_bmc_2015_03_075 crossref_primary_10_1161_JAHA_117_005991 crossref_primary_10_1016_j_bmcl_2016_04_009 crossref_primary_10_1097_FJC_0000000000000269 crossref_primary_10_1160_TH13_09_0805 crossref_primary_10_1016_j_vph_2017_01_003 crossref_primary_10_1051_medsci_20153108006 crossref_primary_10_1080_09537104_2016_1212001 crossref_primary_10_3390_cancers10080253 crossref_primary_10_1007_s10529_017_2346_x |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM |
| DOI | 10.1160/TH13-02-0084 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 24108565 |
| Genre | Journal Article Review |
| GroupedDBID | --- .55 .GJ 0R~ 0VX 123 1KJ 4.4 53G 5RE AAQQT ABJNI ABOCM ACGFO ACGFS ACNUY AENEX AFFNX AGCGI AHRSK ALMA_UNASSIGNED_HOLDINGS BR6 C45 CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P H13 J5H NPM OVD P2P RTC RTE SJN TEORI X7M ZGI ZXP |
| ID | FETCH-LOGICAL-c489t-cf6bc53f1a8039c62ea74d849249a2e4b65c5ec4ceb187d4a485ee563d9293de2 |
| ISSN | 0340-6245 |
| IngestDate | Mon Jul 21 05:23:23 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c489t-cf6bc53f1a8039c62ea74d849249a2e4b65c5ec4ceb187d4a485ee563d9293de2 |
| PMID | 24108565 |
| ParticipantIDs | pubmed_primary_24108565 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-11-01 |
| PublicationDateYYYYMMDD | 2013-11-01 |
| PublicationDate_xml | – month: 11 year: 2013 text: 2013-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Thrombosis and haemostasis |
| PublicationTitleAlternate | Thromb Haemost |
| PublicationYear | 2013 |
| SSID | ssj0016495 |
| Score | 2.2142568 |
| SecondaryResourceType | review_article |
| Snippet | The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 868 |
| SubjectTerms | Animals Cerebrovascular Disorders - drug therapy Clinical Trials as Topic Drug Discovery Humans Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Purinergic P2Y Receptor Antagonists - therapeutic use Receptor, PAR-1 - antagonists & inhibitors Risk Assessment |
| Title | Novel antiplatelet drugs in clinical development |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24108565 |
| Volume | 110 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV05T8MwFLYoSIgFcd8oAxsKpInjOCNUQIVEp1bqVtmOQzs0qUph4Nfznp1L5RCwWJEdWfH74ufP9jsIuQAGrhX1UlewSLm0LTwX3RBchrHXpIi4Tky0zx7rDujjMBzWKf2Md8lCXqn3L_1K_oMq1AGu6CX7B2SrTqECngFfKAFhKH-FcS9_0-jqjyaBwBkBgstk_vpsTFwrl8ekNgtqMtH-eJ5PZY7xSPDsfCz0NAem-DKpSPYAD_wsovVVP16s33Yym0DqoXlm0A4K57latQRo9O_bQI6VHizsSyfNq2a7JNrMN5-1LUPzxH4XE0T4Lobmb74GsppNjeSBJQCzszkhfm5din1dNrVIC3YBmNYUz2KKOyJGTU6daiylWwPzrpufhOGei26Wtg6GQvS3yGbB_Z0bC-Q2WdHZDll_Kqwbdoln8HSaeDoGT2eSOSWeTgPPPTK4v-t3um6R0cJVlMcLV6VMqjBI24J7QayYr0VEE05xEyx8TSULVQhzR8EKyqOECspDrUMWJMBig0T7-2Q1yzN9SBwdyZRq2K2GSlKPJzKONZSCS9DBUosjcmDHOprZsCWjUgrH37ackI36bzklaynME30GpGshz43sPwCNxyfj |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+antiplatelet+drugs+in+clinical+development&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Ungerer%2C+M&rft.au=M%C3%BCnch%2C+G&rft.date=2013-11-01&rft.issn=0340-6245&rft.volume=110&rft.issue=5&rft.spage=868&rft_id=info:doi/10.1160%2FTH13-02-0084&rft_id=info%3Apmid%2F24108565&rft_id=info%3Apmid%2F24108565&rft.externalDocID=24108565 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon |